Joseph Molly 4

What Happened
Joseph Molly, a director of West Pharmaceutical Services, received a grant of 791 restricted stock units (RSUs) reported on a Form 4 for the 2026-05-04 transaction date. The RSUs were reported at an acquisition price of $0.00 (total reported acquisition value $0). This is an award/grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-05-04; Form 4 filed 2026-05-06 (timely filing).
• Transaction type/code: Award/Grant (A).
• Amount: 791 RSUs at $0.00 per unit; reported acquisition value $0.
• Shares/units owned after transaction: not disclosed in the filing.
• Footnote: The RSUs will vest in full on the date of the next annual shareholder meeting.
• No 10b5-1 plan, tax-withholding, or sale details were reported in this filing.

Context
RSUs are a compensation award that convert to actual shares only upon vesting; until then they are a promise of future shares rather than immediate market ownership. Such grants are common for directors and employees and should be viewed as compensation-related rather than a direct buy/sell signal. Monitor the vesting date (next annual shareholder meeting) for when shares may be issued and any subsequent sales or tax-withholding events.